retatrutide triple agonist gip glp-1 glucagon Retatrutide, a GIP, and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA retatrutide triple agonist glp-1 gip

However, we dont yet have studies available that directly compare the two versions

Average 15-21% weight loss* Tailored programmes built by real experts Targeted support to make success feel simpler Unique app with weight loss tools and lessons Your journey starts here Start your personalised weight loss plan in minutes

[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Ferguson D., Finck B

Neurogastroenterol Motil 2017;29

Among medicines approved, liraglutide shows significant effects

Phase 2 and 3 studies, such as randomized controlled trials, have shown that these agents significantly reduce liver fat content, improve liver enzyme profiles, and promote histological improvements in patients with MASLD and MASH (6, 46)